home / stock / adap / adap articles
By Michael Kim READ THE FULL ADAP RESEARCH REPORT We are initiating coverage of Adaptimmune Therapeutics plc (NASDAQ: ADAP) with a 12-month price t...
Shares of SentinelOne, Inc. (NYSE:S) shares fell sharply during Friday's session after the company posted mixed first-quarter results. Sentine...
Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) shares are trading higher by 15.8% to $1.17 during Friday’s session after the company ...
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next generation MAGE-A4 TCR ...
Shares of Marvell Technology, Inc. (NASDAQ: MRVL) fell sharply during Friday’s session after the company reported fourth-quarter financial r...
U.S. stocks were higher, with the Dow Jones index gaining more than 100 points on Friday. Shares of Smith & Wesson Brands, Inc. (NASDAQ: SWBI)...
News, Short Squeeze, Breakout and More Instantly...
Adaptimmune Therapeutics plc Company Name:
ADAP Stock Symbol:
NASDAQ Market:
Adaptimmune Therapeutics plc Website:
Overall response rate of 40% consistent across sarcoma indications; median duration of response ~11 months with patients still in response at time of analysis Interim analysis data reinforces the potential of lete-cel to bolster Adaptimmune's sarcoma franchise by expanding addressable sarcoma pa...
2024-05-31 16:15:02 ET Wells Fargo analyst issues EQUAL-WEIGHT recommendation for ADAP on May 31, 2024 02:43PM ET. The previous analyst recommendation was Equal-Weight. ADAP was trading at $1.135 at issue of the analyst recommendation. The overall analyst consensus : BUY...